RET and non-small cell lung carcinoma: Prasacitinib and selpercatinib are two highly selective RET inhibitors that have achieved a remarkable and sustained response rate of 60%–68% in RET-positive NSCLC patients (Gautschi et al., 2017; Febbo et al., 2011).